CVS Caremark®

|  |
| --- |
| Reference number(s) |
| 4411-A |

# Specialty Guideline Management Orgovyx

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
| --- | --- |
| Orgovyx | relugolix |

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### FDA-approved Indications

Orgovyx is indicated for the treatment of adult patients with advanced prostate cancer.

### Compendial Uses

Prostate Cancer

All other indications are considered experimental/investigational and not medically necessary.

## Coverage Criteria

### Prostate Cancer

Authorization of 12 months may be granted for treatment of prostate cancer.

## Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization who are experiencing clinical benefit to therapy (e.g., maintaining serum testosterone to less than 50ng/dL) and who have not experienced an unacceptable toxicity.

## References

1. Orgovyx [package insert]. Brisbane, CA: Myovant Sciences, Inc; August 2023.
2. The NCCN Drugs & Biologics Compendium® © 2024 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed August 1, 2024.